NCT05013801View on ClinicalTrials.gov

A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma

NACompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 6, 2021

Primary Completion Date

February 25, 2022

Study Completion Date

February 25, 2022

Conditions
Melasma
Interventions
OTHER

Cosmetic facial serum Q69

Cosmetic facial serum

DRUG

2% Hydroquinone

2% Hydroquinone cream

Trial Locations (1)

Unknown

Shanghai Skin Disease Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Skin Disease and Venereal Disease Hospital

OTHER

lead

Unilever R&D

INDUSTRY

NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma | Biotech Hunter | Biotech Hunter